Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMadrigal Pharmaceuticals Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 6 | -$5.25 | -$1.50 | -$4.23 |
| Q2 2026 | 4 | -$3.09 | -$1.97 | -$2.58 |
| Q3 2026 | 4 | -$1.24 | -$0.74 | -$0.96 |
| Q4 2026 | 2 | $0.07 | $0.09 | $0.08 |
| Q1 2027 | 2 | $0.50 | $0.59 | $0.55 |
| Q2 2027 | 1 | $1.73 | $2.04 | $1.92 |
| Q3 2027 | 1 | $2.54 | $3.00 | $2.83 |
| Q4 2027 | 2 | $3.99 | $4.70 | $4.43 |
Madrigal Pharmaceuticals Inc Earnings Date And Information
Madrigal Pharmaceuticals Inc last posted its earnings results on Wednesday, May 6th, 2026. The company reported $-3.25 earnings per share for the quarter, topping analysts' consensus estimates of $-3.61 by $0.36. The company had revenue of 311.34 M for the quarter and had revenue of 958.40 M for the year. Madrigal Pharmaceuticals Inc has generated $-13 earnings per share over the last year ($-12.85 diluted earnings per share) and currently has a price-to-earnings ratio of -40.07. Madrigal Pharmaceuticals Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Madrigal Pharmaceuticals Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/06/2026 | Q1 2026 | -$3.61 | -$3.25 | 0.36 | $301.05 M | $311.34 M |
| 02/19/2026 | Q4 2025 | $0.04 | -$2.57 | -2.61 | $312.51 M | $321.08 M |
| 11/04/2025 | Q3 2025 | -$2.04 | -$5.08 | -3.04 | $247.34 M | $287.27 M |
| 08/05/2025 | Q2 2025 | -$3.48 | -$1.90 | 1.58 | $162.03 M | $212.80 M |
| 05/01/2025 | Q1 2025 | -$3.62 | -$3.32 | 0.3 | $114.66 M | $137.25 M |
| 02/26/2025 | Q4 2024 | -$4.32 | -$2.71 | 1.61 | $99.09 M | $103.32 M |
| 10/31/2024 | Q3 2024 | -$6.94 | -$4.92 | 2.02 | $34.60 M | $62.18 M |
| 08/07/2024 | Q2 2024 | -$7.55 | -$7.10 | 0.45 | $4.25 M | $14.64 M |
| 05/07/2024 | Q1 2024 | -$6.06 | -$7.38 | -1.32 | $114.77 K | $0 |
| 02/28/2024 | Q4 2023 | -$5.32 | -$5.68 | -0.36 | N/A | $0 |
| 11/06/2023 | Q3 2023 | -$4.78 | -$5.34 | -0.56 | N/A | $0 |
| 08/08/2023 | Q2 2023 | -$4.47 | -$4.69 | -0.22 | N/A | $0 |
| 05/09/2023 | Q1 2023 | -$4.98 | -$4.23 | 0.75 | N/A | $0 |
| 02/23/2023 | Q4 2022 | -$4.41 | -$4.98 | -0.57 | N/A | $0 |
| 11/03/2022 | Q3 2022 | -$4.05 | -$4.75 | -0.7 | N/A | $0 |
| 08/04/2022 | Q2 2022 | -$3.76 | -$4.14 | -0.38 | N/A | $0 |
| 05/09/2022 | Q1 2022 | -$3.75 | -$3.36 | 0.39 | N/A | $0 |
| 02/24/2022 | Q4 2021 | -$3.92 | -$3.78 | 0.14 | N/A | $0 |
| 11/04/2021 | Q3 2021 | -$3.89 | -$3.79 | 0.1 | N/A | $0 |
| 08/05/2021 | Q2 2021 | -$3.55 | -$3.72 | -0.17 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Madrigal Pharmaceuticals Inc Earnings: FAQ's
In the previous quarter, Madrigal Pharmaceuticals Inc (:MDGL) reported $-3.25 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.61 by $0.36.
The conference call for Madrigal Pharmaceuticals Inc's latest earnings report can be listened to online.
The conference call transcript for Madrigal Pharmaceuticals Inc's latest earnings report can be read online.
Madrigal Pharmaceuticals Inc (:MDGL) has a recorded annual revenue of $958.40 M.
Madrigal Pharmaceuticals Inc (:MDGL) has a recorded net income of $-288,284,000.Madrigal Pharmaceuticals Inc has generated $-12.85 earnings per share over the last four quarters.
Madrigal Pharmaceuticals Inc (:MDGL) has a price-to-earnings ratio of -40.07 and price/earnings-to-growth ratio is -1.37.